Evidence map›Paper›PMID 31406927›Full record

ArticleJGH open : an open access journal of gastroenterology and hepatology2019

Skeletal muscle mass is associated with toxicity, treatment tolerability, and additional or subsequent therapies in patients with hepatocellular carcinoma receiving sorafenib treatment.

Koji Sawada, Yoshinori Saitho, Hidemi Hayashi, Takumu Hasebe, Shunsuke Nakajima, Katsuya Ikuta, Mikihiro Fujiya, Toshikatsu Okumura

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JGH open : an open access journal of gastroenterology and hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Observational
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Koji SawadaDepartment of Medicine, Division of Gastroenterology and Hematology/Oncology Asahikawa Medical University Asahikawa Japan.ORCID https://orcid.org/0000-0002-9708-4786
Yoshinori SaithoDepartment of Gastroenterology Asahikawa Kosei General Hospital Asahikawa Japan.
Hidemi HayashiDepartment of Medicine, Division of Gastroenterology and Hematology/Oncology Asahikawa Medical University Asahikawa Japan.
Takumu HasebeDepartment of Medicine, Division of Gastroenterology and Hematology/Oncology Asahikawa Medical University Asahikawa Japan.
Shunsuke NakajimaDepartment of Medicine, Division of Gastroenterology and Hematology/Oncology Asahikawa Medical University Asahikawa Japan.
Katsuya IkutaDepartment of Medicine, Division of Gastroenterology and Hematology/Oncology Asahikawa Medical University Asahikawa Japan.
Mikihiro FujiyaDepartment of Medicine, Division of Gastroenterology and Hematology/Oncology Asahikawa Medical University Asahikawa Japan.
Toshikatsu OkumuraDepartment of Medicine, Division of Gastroenterology and Hematology/Oncology Asahikawa Medical University Asahikawa Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimSeveral reports have demonstrated that skeletal muscle mass influences mortality in patients with hepatocellular carcinoma (HCC) receiving sorafenib treatment; however, there is still controversy with regard to whether skeletal muscle and adipose tissue are associated with the prognosis in HCC patients. We examined the relationship between body composition and prognosis in HCC patients.

methodsWe retrospectively analyzed 82 patients with unresectable HCC receiving sorafenib treatment. The skeletal muscle area and adipose tissue area were measured by computed tomography. Patients with low skeletal muscle index (male ≤36.2 cm

resultsA total of 16 and 34 patients were classified as LSMM and high VSR, respectively. LSMM patients frequently experienced serious adverse events (SAEs) and thus had a shorter duration of sorafenib treatment than non-LSMM patients. High VSR was a significant factor for progression-free survival. LSMM patients less frequently received additional/subsequent therapies combined with sorafenib than non-LSMM patients. Multivariate Cox hazard analysis demonstrated that LSMM was a significant factor for the duration of sorafenib treatment. The treatment duration and receiving of additional/subsequent therapies were significantly associated with overall survival (OS) but not with LSMM or high VSR.

conclusionLSMM was associated with the frequency of SAEs, treatment tolerability, and treatment duration. LSMM patients were less likely to receive additional/subsequent therapies than non-LSMM patients. Thus, LSMM could identify a subgroup of patients with poor OS.

Indexed as

additional and subsequent therapiesduration of treatmenthepatocellular carcinomaskeletal musclesorafenibvisceral to subcutaneous adipose tissue area ratio

Identifiers

PMID31406927
PMCPMC6684515

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.